Mediwound Ltd (MDWD)

Currency in USD
20.000
-0.010(-0.05%)
Closed·
After Hours
20.0000.000(0.00%)
·
MDWD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MDWD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
19.73020.526
52 wk Range
14.14022.505
Key Statistics
Prev. Close
20.01
Open
20.02
Day's Range
19.73-20.526
52 wk Range
14.14-22.505
Volume
58.95K
Average Vol. (3m)
64.85K
1-Year Change
-1.96%
Book Value / Share
2.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MDWD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
30.667
Upside
+53.33%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Mediwound Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Mediwound Ltd Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Employees
111

Mediwound Ltd Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of -$0.36 beat expectations; revenue reached $5.84M, slightly above forecast
  • Full-year 2024 revenue increased to $20.2M from $18.7M in 2023; net loss of $30.2M or $3.03 per share
  • NexoBrid 2025 revenue projected at $24M; Phase 3 VLU Global Trial for EscharEx interim analysis expected mid-2026
  • Stock closed at $19.19, down 0.42% pre-market despite earnings beat; analysts maintain bullish outlook
  • Strong liquidity with current ratio of 2.11; cash position of $43.6M at year-end
Last Updated: 03/19/2025, 09:39 AM
Read Full Transcript

Compare MDWD to Peers and Sector

Metrics to compare
MDWD
Peers
Sector
Relationship
P/E Ratio
−10.2x−0.1x−0.5x
PEG Ratio
0.210.000.00
Price / Book
6.9x0.0x2.6x
Price / LTM Sales
11.3x0.6x3.2x
Upside (Analyst Target)
52.4%171.4%45.3%
Fair Value Upside
Unlock21.6%7.4%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 30.667
(+53.33% Upside)

Earnings

Latest Release
May 21, 2025
EPS / Forecast
-0.07 / -0.645
Revenue / Forecast
3.96M / 5.08M
EPS Revisions
Last 90 days

MDWD Income Statement

People Also Watch

109.69
AZZ
+3.22%
2.86
RCKT
+1.78%
3.860
SQNS
-18.22%
6.71
MDXG
+6.00%
2.350
PRQR
-0.42%

FAQ

What Is the Mediwound (MDWD) Stock Price Today?

The Mediwound stock price today is 20.00

What Stock Exchange Does Mediwound Trade On?

Mediwound is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Mediwound?

The stock symbol for Mediwound is "MDWD."

What Is the Mediwound Market Cap?

As of today, Mediwound market cap is 216.26M.

What Is Mediwound's Earnings Per Share (TTM)?

The Mediwound EPS (TTM) is -2.05.

When Is the Next Mediwound Earnings Date?

Mediwound will release its next earnings report on Aug 12, 2025.

From a Technical Analysis Perspective, Is MDWD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Mediwound Stock Split?

Mediwound has split 1 times.

How Many Employees Does Mediwound Have?

Mediwound has 111 employees.

What is the current trading status of Mediwound (MDWD)?

As of Jul 17, 2025, Mediwound (MDWD) is trading at a price of 20.00, with a previous close of 20.01. The stock has fluctuated within a day range of 19.73 to 20.53, while its 52-week range spans from 14.14 to 22.51.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.